DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/a76108/watson_pharmaceuti) has announced the addition of the "Watson Pharmaceuticals Generics Company Intelligence Report" report to their offering.
Watson Pharmaceuticals was founded in 1984 in Corona, California. The company has facilities across the USA, and in the UK and China. It vies with Barr and Mylan as the USAs largest generic manufacturer.
Watsons sales for 2009 stood at US$2,793.0 million, an increase of 10.2% over the US$2,535.5 million reported for 2008. Generic net revenues amounted to US$1,668.2 million, up by 13.2% over the US$1,474.3 million reported for 2008.
The company has always had a small branded business, introducing its first branded product in 1996. In February 2003, the FDA approved Oxytrol, the companys oxybutin product. This is the first product Watson has fully developed from conception to manufacturing and distribution.
In March 2006, Watson announced it had entered into an agreement to acquire the outstanding stock of Andrx, in a deal worth some US$1.9 billion. The deal was completed in November 2006.
In June 2009, Watson announced plans to acquire the Arrow Group for US$1.75 billion in cash and stocks. The acquisition would give the firm commercial operations in over 20 countries. It closed in late 2009; Watson believes it will be a pivotal acquisition.
Key Topics Covered:
1. Executive Summary
4. Financial Results
5. Major Developments
6. Contact Details
- Sekhsaria Chemicals
For more information visit http://www.researchandmarkets.com/research/a76108/watson_pharmaceuti
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: United States North America
INDUSTRY KEYWORDS: Health Pharmaceutical